The global generic drugs market size reached USD 464.98 billion in 2023 and is estimated to surpass around USD 776.78 billion by 2033, notable at a CAGR of 5.2% from 2024 to 2033.
Key Points
- North America led the global market with the highest market share of 34.69% in 2023.
- By brand, the pure generics segment has held the largest market share of 52.57% in 2023.
- By route of administration, the oral segment captured the biggest revenue share of 65.33% in 2023.
- By drug type, the simple generic segment is estimated to hold the highest market share of 60.74% in 2023.
- By therapeutic application, the oncology segment is expected to grow at a remarkable CAGR of 6.6% during the forecast period.
A generic drug comprises the same chemical substance as a drug that was previously protected by a chemical patent. After the patents on the original pharmaceuticals expire, generic drugs can be sold. The medical profile of generics is thought to be equal in performance because the active chemical ingredient is the same. Generic medicine contains the same active pharmaceutical ingredient (API) as the brand-name drug, but it may change in terms of manufacturing technique, formulation, excipients, color, taste, and packaging. The cost effectiveness of generic drugs has contributed for a competitive advantage over the branded drugs is the prime factor adding boost to the market growth.
Get a Sample: https://www.precedenceresearch.com/sample/1205
Crucial factors accountable for market growth are:
- The low cost of generics as an alternative to branded drugs
- A large number of patents expired branded drugs
- Initiatives by governments and other regulatory bodies across the globe
Patent expiry of branded drugs to open up novel avenues for generic drug players to penetrate in the market
The patent expiry of branded drugs is continuously increasing providing huge potential opportunities in the drugs market. The manufacturers of generic drugs have persistently focused on development and launch of different innovative medication as well as formulation such as biosimilars that is adding traction to the market growth. Additionally, the government initiatives to promote manufacturing of generic drugs against fatal chronic diseases have further propelled the market growth in emerging economiesspecifically. Furthermore, the growing ageing populations across the globe, who are more prone to various diseases have added fuel to the market growth.
The key advantages associated with oral generics such as the comfort of drug administration via the oral route, patient preference, cost-effectiveness, and ease of large-scale manufacture of oral dosage forms, oral medication is the most prevalent way of drug administration. Approximately 65 percent of commercially available generic medication medicines are taken orally. Oral formulations account for around 90% of the global market share of all pharmaceutical formulations intended for human use, according to current estimates. Orally administered pharmaceuticals account for about 84 percent of the top-selling pharmaceuticals. They are the key contributor for the market growth owing to the favored as well as cheap option. Also, they are patient-friendly, especially in the geriatric and pediatric populations, and are comparatively easy to create in comparison to their big molecule rivals.
Generic Drugs Market Scope
| Report Highlights | Details |
| Market Size in 2023 | USD 464.98 Billion |
| Market Size by 2033 | USD 776.78 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 5.2% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Drug, Brand, Route of Drug Administration, Therapeutic Application, Distribution Channel |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
KEY HIGHLIGHTS OF THE STUDY
- The oral segment of route of administration is estimated to grow at the remarkable rate and accounted the largest share throughout the study period.
- Branded generics dominate the generic drugs market in 2020, however pure generics is anticipated to surpass branded generics by 2027.
- Asia Pacific region is projected to grow at the fastest CAGR during the forecast period owing to the rapid penetration of local players in the market.
- North America dominated the generic drugsmarket and is projected to retain its trend throughout the forecast period.
- Cardiovascular of the therapeutic application segment exhibited major revenue share in the year 2020, whereas, oncology segment poised to grow at the fastest rate during the foresee future.
- Retail pharmacy holds the leading position in distribution channel segment; however, online distribution is growing at the significant pace during the forecast period.
Asia Pacific region to gain traction in global generic drugs market owing to the lower manufacturing cost and high skilled workforce
Asia Pacific is expected to show a significant traction in the market over the forecast period. This is attributed to lower manufacturing costs and high skilled workforce in the Asian countries. According to India Brand Equity Foundation, India has the second largest number of U.S. FDA manufacturing plants outside the U.S. that are involved in generic drugs manufacturing. Additionally, the cost of manufacturing is 33% lower in India than that in the U.S., increasing accessibility to generics in these countries.
Asia-Pacific has placed a strong emphasis on boosting medicine procurement at more inexpensive prices, even if this necessitates buying from non-traditional sources, with a historically low rate of generic drug use. Therefore, emerging nations such as India and China is supplementing the growth of generics market.
In 2019, generic and biosimilar pharmaceuticals saved the US healthcare system $313 billion, including $96 billion in Medicare savings and $48.5 billion in Medicaid savings. Generics fill 90% of prescriptions in the United States for only 20% of the cost, at a time when access to reliable, inexpensive, and high-quality prescription medication is more critical than ever. In 2019, the average generic primary copay was $6.97 versus average primary copay for brand-name drugs of $56.32. These supporting factors are expected to drive generic drug sales over the next few years.
Read Also: Patient Monitoring Devices Market Size, Share, Report 2032
Market Competitiveness and Business Outlook
The global generic drugs market is fragmented owing to the presence of several large and small scale firms spread across the globe. The leading players in the market are adopting novel strategies to gain market attractiveness.The report provides an extensive competitive analysis and profiles of the key market players, such as Mylan N.V., Abbott Laboratories, ALLERGAN, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, STADA Arzneimittel AG, GlaxoSmithKline Plc., Baxter International Inc., Pfizer Inc., Sandoz International GmbH and others. Theother players operating in the value chain are AurbindoPharma, Sun Pharmaceutical Industries Ltd., Aspen Pharmacare, Fresenius Kabi Ag, Lupin, Novartis, Glenmark, Sawai, PiramalPharma Solutions, Hikma, Cipla, Dr. Reddy’s, Endo, Stada and Mallinckrod among others.
Recent Developments
- In March 2019, Allergan acquired Envy Medical, a biotechnology company providing dermatology and medical aesthetics solutions
- In September 2018, Allergan acquired Bonti Endurance Biotech, a biotechnology company based in Orange, California.
- In 2018, Allergan has acquired Elastagen a leading player. This is order to increase the product portfolio which helps to maintain skin’s elasticity.
Generic Drugs Market Companies
- Mylan N.V.
- Abbott Laboratories
- ALLERGAN
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- STADA Arzneimittel AG
- GlaxoSmithKline Plc.
- Baxter International Inc.
- Pfizer Inc.
- Sandoz International GmbH
Segments Covered in the Report
By Drug Type
- Simple Generics
- Super Generics
By Brand
- Pure generic drugs
- Branded generic drugs
By Route of Drug Administration
- Oral
- Injection
- Cutaneous
- Others
By Therapeutic Application
- Central Nervous System (CNS)
- Cardiovascular
- Infectious Diseases
- Musculoskeletal Diseases
- Respiratory
- Oncology
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online and Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/